RENAU.UNSP.ARD 1/5 EO-20 (56S0) - Cash Flow Conversion Efficiency
Based on the latest financial reports, RENAU.UNSP.ARD 1/5 EO-20 (56S0) has a cash flow conversion efficiency ratio of 0.047x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€193.30 Million ≈ $225.99 Million USD) by net assets (€4.14 Billion ≈ $4.84 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 56S0 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
RENAU.UNSP.ARD 1/5 EO-20 - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how RENAU.UNSP.ARD 1/5 EO-20's cash flow conversion efficiency has evolved over time, based on yearly financial data.
RENAU.UNSP.ARD 1/5 EO-20 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of RENAU.UNSP.ARD 1/5 EO-20 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
YANGTZE OPT.FIB.AND CAB.H
F:1YO
|
N/A |
|
PTT Exploration and Production Public Company Limited
F:NVAL
|
0.085x |
|
Hua Xia Bank Co Ltd
SHG:600015
|
-0.089x |
|
Banco Santander Chile
SN:BSANTANDER
|
-0.075x |
|
China International Capital Corp Ltd
SHG:601995
|
0.302x |
|
Taiwan Union Technology
TWO:6274
|
-0.087x |
|
Jde Peets Nv
AS:JDEP
|
0.066x |
|
Power Finance Corporation Limited
NSE:PFC
|
-0.052x |
Annual Cash Flow Conversion Efficiency for RENAU.UNSP.ARD 1/5 EO-20 (2022–2025)
The table below shows the annual cash flow conversion efficiency of RENAU.UNSP.ARD 1/5 EO-20 from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see RENAU.UNSP.ARD 1/5 EO-20 market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €4.13 Billion ≈ $4.82 Billion |
€692.20 Million ≈ $809.25 Million |
0.168x | -17.18% |
| 2024-12-31 | €4.02 Billion ≈ $4.70 Billion |
€815.10 Million ≈ $952.94 Million |
0.203x | -27.43% |
| 2023-12-31 | €2.67 Billion ≈ $3.13 Billion |
€746.40 Million ≈ $872.62 Million |
0.279x | +14.62% |
| 2022-12-31 | €2.51 Billion ≈ $2.94 Billion |
€612.30 Million ≈ $715.84 Million |
0.244x | -- |
About RENAU.UNSP.ARD 1/5 EO-20
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transp… Read more